Michele Cree, Children’s Health Queensland Pharmacist Lead (Critical Care) and PhD student with the CRE RESPOND team at The University of Queensland’s Frazer Institute, has been recognised in the CHQ Research Impact Report 2025 for her outstanding contribution to paediatric critical care research.
Michele’s feature highlights her leadership of a landmark pharmacokinetic study examining how lifesaving organ support technologies — ECMO and CRRT — influence the behaviour of antibiotics and antifungal medicines in critically ill children. Her research revealed that over 60% of antimicrobials tested were lost within ECMO circuits, a finding that underscores the urgent need to refine dosing strategies to ensure safe and effective treatment for paediatric patients requiring advanced organ support.
Her inclusion in the Research Impact Report reflects not only the significance of these findings, but also her broader contribution to improving medication safety and antimicrobial stewardship across paediatric intensive care. Through her PhD, Michele works closely with CRE RESPOND, bringing her clinical expertise into research that is already influencing practice in Australia and internationally.
The CHQ Research Impact Report recognises researchers whose work is shaping the future of child health. Michele’s feature acknowledges her dedication to advancing evidence‑based care, her leadership within multidisciplinary teams, and her commitment to improving outcomes for critically ill children. Her achievements demonstrate the vital role of clinician‑researchers in driving innovation and ensuring that lifesaving therapies are supported by robust, paediatric‑specific evidence.
Read the full Children’s Health Queensland Research Impact Report 2025
